abstract |
The present invention relates to a model, in particular a murine model, for assessing toxicity for immunotherapy, for example a cell therapy, such as a cell therapy containing modified cells, such as T cells, expressing a recombinant receptor, by example a chimeric antigen receptor (CAR). The invention also relates to a method for producing the mouse model. The invention also provides methods of use for mouse models of toxicity, for example to evaluate modified or alternative immunotherapies, and / or to evaluate test agents, including agents to be evaluated as potential interventions for to reduce, prevent, or mitigate toxicity to immunotherapy in human subjects and / or for use in combination with immunotherapy, such as CAR-T cell therapy. |